SIGA Technologies is a public, commercial-stage pharmaceutical company focused on providing solutions for unmet needs in health security, which comprises medical countermeasures against chemical, biological, radiological, and nuclear threats as well as emerging infectious diseases. Our product, oral TPOXX® (tecovirimat), is the first drug approved by the U.S. FDA that is specifically indicated for the treatment of smallpox disease and would play a critical role in responding to a smallpox bioterror attack.